Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

15.01 +0.15 (+1.01%)

Streaming Delayed Price Updated: 10:02 AM EST, Feb 13, 2026 Add to My Watchlist

Price and Volume

Volume	4,162
Open	14.73
Bid (Size)	14.83 (100)
Ask (Size)	15.20 (100)
Prev. Close	14.86
Today's Range	14.73 - 15.11
52wk Range	7.080 - 20.90
Shares Outstanding	407,265,944
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

February 11, 2026

From Amarin Corporation plc

Via GlobeNewswire

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

January 09, 2026

From Amarin Corporation plc

Via GlobeNewswire

Performance

YTD	+9.4%	+9.4%
1 Month	-1.0%	-1.0%
3 Month	-7.7%	-7.7%
6 Month	-0.2%	-0.2%
1 Year	+34.0%	+34.0%

More News

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Earnings Outlook For Amarin Corp ↗

October 28, 2025

Via Benzinga

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities

January 08, 2026

From Amarin Corporation plc

Via GlobeNewswire

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

November 09, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

November 03, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin Corp (NASDAQ:AMRN) Beats Q3 2025 Earnings and Revenue Estimates ↗

October 29, 2025

Via Chartmill

Amarin Reports Third Quarter 2025 Financial Results

October 29, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit

October 27, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025

October 15, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

October 14, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

August 31, 2025

From Amarin Corporation plc

Via GlobeNewswire

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

August 30, 2025

From Amarin Corporation plc

Via GlobeNewswire

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

August 25, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin Reports Second Quarter 2025 Financial Results

July 30, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

July 23, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA ↗

June 24, 2025

Via Benzinga

Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges ↗

June 24, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 24, 2025

Via Benzinga

Which stocks are gapping on Tuesday? ↗

June 24, 2025

Via Chartmill

Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

June 24, 2025

From Amarin Corporation plc

Via GlobeNewswire

Amarin Reports First Quarter 2025 Financial Results

May 07, 2025

From Amarin Corporation plc

Via GlobeNewswire

Frequently Asked Questions

Is Amarin Corporation plc - American Depositary Shares publicly traded?

Yes, Amarin Corporation plc - American Depositary Shares is publicly traded.

What exchange does Amarin Corporation plc - American Depositary Shares trade on?

Amarin Corporation plc - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Amarin Corporation plc - American Depositary Shares?

The ticker symbol for Amarin Corporation plc - American Depositary Shares is AMRN on the Nasdaq Stock Market

What is the current price of Amarin Corporation plc - American Depositary Shares?

The current price of Amarin Corporation plc - American Depositary Shares is 15.01

When was Amarin Corporation plc - American Depositary Shares last traded?

The last trade of Amarin Corporation plc - American Depositary Shares was at 02/13/26 10:02 AM ET

What is the market capitalization of Amarin Corporation plc - American Depositary Shares?

The market capitalization of Amarin Corporation plc - American Depositary Shares is 6.11B

How many shares of Amarin Corporation plc - American Depositary Shares are outstanding?

Amarin Corporation plc - American Depositary Shares has 6B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.